Henoch-Schonlein purpura
Conditions
Interventions
Control Group:The control group will receive modern medicine treatment: For patients over 12 years old, loratadine tablets 10mg will be administered orally once daily
for patients under 12 years old, those with a body weight > 30kg will receive loratadine tablets 10mg orally once daily, and those with a body weight = 30kg will receive loratadine tablets 5mg orally
for patients with abdominal pain, arthritis, or renal-type Henoch-Schonlein purpura, prednisone acetate tablets 1-2mg/(kg·d) (maximum dose 60mg/d) will be administered for 2 weeks, and the dose will b
Experimental Group:The experimental group will receive the same modern medicine treatment regimen as the control group, plus oral administration of Gurigumu-8 Powder. The dosage regimen of Gurigumu-8
Sponsors
Inner Mongolia International Mongolian Hospital
Eligibility
Sex/Gender
All
Age
8 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) Aged between 8 and 80 years, with no restriction on gender; (2) Meeting the diagnostic criteria of Henoch-Schonlein purpura in modern medicine; (3) Being in the acute phase of Henoch-Schonlein purpura at the initial diagnosis (within 2 weeks after onset); (4) Voluntarily participating in this clinical study and signing the informed consent form (for minor patients, the guardian shall be informed and sign the informed consent form).
Exclusion criteria
Exclusion criteria: (1) Accompanied by severe digestive system symptoms such as severe abdominal pain, severe hematochezia; or accompanied by severe active bleeding and severe infection; or accompanied by severe skin rashes (such as rapidly progressive, hemorrhagic bullous, ulcerative or necrotic rashes); or accompanied by obvious renal damage (e.g., nephrotic syndrome); (2) Having used hormones within the past 1 month; (3) Having coagulation dysfunction, or suffering from hematological, tumor, or immune system diseases; (4) Alanine aminotransferase (ALT), aspartate aminotransferase (AST), bilirubin, or serum creatinine exceeding 1.5 times the upper limit of normal value; (5) Complicated with severe primary diseases of cardiovascular, cerebrovascular, liver, kidney and other systems, or complicated with mental diseases; (6) Known or suspected allergy to the study drug and its excipients; (7) Having participated in or being participating in other clinical trials within the past 1 month; (8) Pregnant or lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| effective rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| symptom relief time;recurrence rate;intestinal flora indicators;serum immunological indicators; | — |
Countries
China
Contacts
Public ContactLang Haiyan
Inner Mongolia International Mongolian Hospital
Outcome results
None listed